Gene Therapy is a medical approach that modifies genetic material within a patient's cells to treat, prevent or potentially cure disease. Genetic modification can involve adding a functional gene, replacing or correcting a defective sequence, disrupting a harmful gene, modifying gene expression or introducing genetic instructions that cause cells to perform a therapeutic function.
Gene therapy can be performed in vivo, in which the therapeutic genetic material is delivered directly into the body, or ex vivo, in which cells are removed, genetically modified outside the body and then returned to the patient. The field encompasses a wide range of technologies rather than one treatment method and can address inherited disorders as well as certain cancers and other acquired diseases.
Traditional gene addition approaches introduce a functional genetic sequence into cells without necessarily correcting the original defective gene. Viral vectors are frequently used because viruses have evolved mechanisms for entering cells and delivering genetic material, although the therapeutic vectors are engineered to reduce or eliminate their disease-causing properties. Adeno-associated virus vectors are used for delivery of certain genes to particular tissues, while lentiviral vectors are commonly used for ex vivo modification of blood-forming or immune cells. Non-viral delivery systems, including lipid-based particles and other engineered carriers, can also transport nucleic acids. Each platform has different characteristics concerning tissue targeting, payload capacity, duration of expression, immunogenicity and manufacturing complexity.
Gene Therapy also includes genome-editing technologies that attempt to modify DNA at a defined genomic location. Systems based on CRISPR-associated proteins can be programmed using guide sequences to recognise particular DNA targets, enabling gene disruption, correction or other forms of editing. Base editing and prime editing extend the conceptual range by enabling certain sequence changes without creating the same type of DNA double-strand break used in conventional CRISPR editing. Precision is not absolute, however, and unintended genomic alterations, incomplete editing and cellular heterogeneity remain important considerations. The therapeutic objective is therefore not simply to edit DNA but to produce a predictable and clinically meaningful biological effect while controlling unintended consequences.
Ex vivo Gene Therapy is particularly useful when target cells can be isolated, genetically modified under controlled manufacturing conditions and returned to the patient. Haematopoietic stem cells are an important example because modified cells can repopulate the blood and immune system after conditioning. Another approach involves modifying a patient's T cells to recognise cancer cells, creating genetically engineered cellular therapies.
Ex vivo manufacturing permits extensive testing of the cell product before administration but is logistically complex and can involve specialised facilities, personalised production and substantial costs. In vivo therapy avoids cell harvesting but introduces challenges of delivering the genetic material specifically to the desired tissues while limiting off-target exposure and immune responses.
Gene Therapy has major applications in inherited diseases because correcting or supplementing a defective genetic function can address an upstream cause rather than merely treating symptoms. Potential targets include disorders affecting the blood, retina, neuromuscular system, immune system and other tissues. Cancer applications differ because the objective may be to alter immune cells, introduce tumour-suppressive functions or modify cellular responses rather than correct a single inherited mutation.
The suitability of gene therapy depends on disease biology, target-cell accessibility, genetic architecture, vector characteristics and whether sufficient numbers of cells can be modified. Disorders involving a single well-defined gene defect can be conceptually more straightforward than diseases involving many interacting genetic and environmental factors.
Safety and durability are central issues. Viral vectors can trigger immune responses that reduce treatment effectiveness or cause inflammatory complications. Some gene-delivery systems can produce long-lasting expression, while others are transient and may require repeat administration. Genome integration can theoretically disrupt host genes or regulatory regions, although vector design has evolved to reduce particular risks. Genome editing introduces additional concerns about unintended edits and long-term genomic consequences. Clinical trials therefore require extensive monitoring, including assessment of immune reactions, organ toxicity, abnormal cell growth and persistence of the therapeutic effect. Long-term follow-up can be particularly important for treatments that permanently alter cellular genomes.
Gene-therapy manufacturing is technically demanding because the final product may consist of viral vectors, genetically modified cells or other complex biological materials. Manufacturing requires control of identity, purity, potency, sterility and genetic characteristics. For personalised therapies, every patient's product may require separate collection, modification, testing and release procedures. Regulatory assessment considers the specific therapeutic product, indication, manufacturing process and evidence of clinical benefit rather than treating gene therapy as a single homogeneous category. Cost, infrastructure, specialist expertise and access to appropriate follow-up can therefore influence whether a technically successful therapy becomes broadly available.
Gene Therapy should be distinguished from gene replacement, genome editing, conventional drug therapy and inherited genetic testing. A conventional drug generally modifies biological pathways without permanently altering the patient's DNA, although some modern nucleic-acid medicines can alter gene expression without changing genomic sequence. Gene therapy also does not ordinarily mean altering the DNA of a future child through reproductive-line intervention; somatic gene therapy targets cells of an individual patient, while germline modification raises separate scientific, ethical and legal questions and is treated differently across jurisdictions.
A common misconception is that successful genetic correction necessarily provides immediate or universal cure; effectiveness depends on delivery, target cells, disease stage, biological response and durability. The field's significance lies in its ability to intervene at the genetic level while requiring unusually rigorous attention to long-term safety and manufacturing quality.
